A Drug That Regrows Natural Teeth Enters Phase II Human Trials

For generations, the loss of a permanent tooth has meant relying on mechanical replacements—dentures, bridges, or titanium implants. Dentistry has long been a discipline of patching and substituting rather than healing. But a fundamental shift is underway as researchers move closer to a biological holy grail: regrowing natural teeth directly in the human jaw. The concept, once relegated to science fiction, is now entering advanced human trials, promising to transform restorative dentistry from a mechanical engineering challenge into a biological regeneration process.[8]

The catalyst for this shift is TRG035, an experimental monoclonal antibody developed by Toregem BioPharma, a biotechnology spin-out from Kyoto University. Following successful Phase I safety trials in healthy adult men—which concluded without any serious adverse events—the company has just secured $5.3 million in Pre-Series C funding. This brings its total financial backing, including government grants and subsidies, to over $29 million. This capital injection clears the way for Phase II clinical trials in Japan, marking a critical milestone in the drug's path toward commercial viability and moving the treatment out of the laboratory and into targeted patient populations.[1][2][3]

The upcoming Phase II trials will specifically target patients with severe congenital hypodontia, a rare genetic condition where individuals are born missing six or more permanent teeth. For these pediatric patients, the clinical stakes are immense. Traditional titanium implants cannot be safely placed until a child's jawbone has completely finished growing. As a result, children with severe hypodontia are often forced to rely on removable dentures for years, which can severely impair their speech development, nutritional intake, and overall facial bone structure.[2][5]

To understand how TRG035 achieves what was previously thought impossible, one must look at the biological "brakes" that prevent humans from growing more than two sets of teeth. The key player in this regulatory system is a specific protein called Uterine Sensitization-Associated Gene-1, commonly referred to as USAG-1. In the human body, USAG-1 acts as a strict developmental gatekeeper, ensuring that tooth formation ceases once our primary and permanent teeth have fully erupted. By studying mice genetically deficient in this protein, researchers discovered that the absence of USAG-1 leads to hyperdontia—the unchecked growth of excessive teeth—revealing its primary role as a negative regulator of dental morphogenesis.[4][6]

At a molecular level, USAG-1 functions as a dual antagonist, actively suppressing two critical signaling pathways known as BMP (Bone Morphogenetic Protein) and Wnt. Both of these pathways are master regulators of odontogenesis, the complex biological process of tooth development. By binding to these signaling molecules and their co-receptors, USAG-1 effectively silences the genetic instructions required to build new dental tissue, locking the jaw into a state of developmental arrest. This evolutionary mechanism prevents the jaw from becoming overcrowded with aberrant mineralization, but it also permanently shuts the door on natural regeneration once a permanent tooth is lost.[4][5]

The specific roles of these pathways highlight why they are so vital to the regenerative process. BMP signaling governs the differentiation of dental stem cells and orchestrates the formation of the tooth's core structural components: the hard outer enamel, the underlying dentin, and the sensitive inner pulp. Meanwhile, Wnt signaling directs cellular proliferation, tissue patterning, and the initial initiation of the tooth buds. Without the active, coordinated participation of both pathways, a new tooth simply cannot take shape, which is why USAG-1's dual-blocking action is so incredibly effective at halting regeneration.[4]

However, researchers made a groundbreaking discovery that upended decades of dental dogma: humans actually retain vestigial "third dentition" tooth buds deep within the jaw. These dormant primordia have the latent potential to become a complete third set of teeth, much like the continuously regenerating teeth seen in certain animal species like sharks or alligators. Under normal circumstances, the constant presence of USAG-1 keeps these rudimentary buds permanently locked in their dormant state, preventing them from ever maturing or erupting through the gumline. The realization that the raw materials for new teeth were already present in the jaw shifted the scientific focus from implanting foreign stem cells to simply waking up the body's existing biology.[2][7]

TRG035 is explicitly designed to release that biological brake. Administered as an intravenous injection, the monoclonal antibody circulates systemically and binds directly to the USAG-1 protein, neutralizing its inhibitory effects. By selectively interfering with USAG-1's ability to block BMP signaling, the drug effectively removes the suppression on the dormant tooth buds. Once the BMP pathway is liberated, the dormant primordia awaken and resume their natural developmental cycle, utilizing the body's own stem cells and signaling cascades to construct a brand new tooth from the inside out.[3][7]

Preclinical trials in animal models provided striking evidence of this mechanism in action. When researchers administered the anti-USAG-1 antibody to mice and ferrets—animals specifically chosen because their diphyodont dental patterns closely resemble the primary and permanent tooth cycles of humans—the subjects successfully grew whole, functional teeth. These regenerated teeth were not mere biological approximations or disorganized masses of calcium. They featured proper, highly structured enamel and dentin layers and demonstrated full biological integration with the surrounding jawbone, ensuring the necessary stability and alignment required for normal chewing function.[1][4]

The undeniable success of these animal models paved the way for TRG035 to receive "Orphan Medicinal Product" designation from Japan's Ministry of Health, Labour and Welfare. This coveted regulatory status provides Toregem BioPharma with vital financial and administrative incentives—including tax benefits, substantial research grants, reduced regulatory fees, and priority clinical review. The designation is specifically designed to accelerate the drug's development for rare congenital conditions like severe hypodontia, ensuring that pediatric patients who have historically lacked effective biological treatments can access the therapy as quickly and safely as possible.[5]

While the immediate clinical focus remains strictly on congenital agenesis, Toregem BioPharma's ultimate ambition is far broader and vastly more lucrative. The company aims to commercialize the treatment for the general public by 2030, targeting the tens of millions of adults worldwide who have lost permanent teeth due to severe decay, advanced periodontal disease, or traumatic injury. If successful, TRG035 would offer a non-invasive, purely biological alternative to the titanium screws, bone grafts, and porcelain crowns that currently dominate the restorative dental industry, fundamentally altering how dentists approach tooth loss.[1][6]

Transitioning from congenital conditions in children to acquired tooth loss in older adults, however, presents significant biological hurdles that have left some experts deeply skeptical. Critics within the scientific community caution that adult jaws may no longer possess the necessary dental epithelial cells required to form a new tooth, even if the USAG-1 brake is successfully removed. While children's jaws are highly plastic and rich in these foundational stem cells, adults who have been missing teeth for decades may find that their dormant buds have degraded or ossified beyond the point of biological reactivation.[1]

Another major clinical challenge lies in localized targeting and spatial control. Because TRG035 is currently administered systemically via intravenous injection, researchers must ensure that neutralizing the USAG-1 protein does not inadvertently trigger unwanted tooth growth in adjacent, healthy areas of the mouth. The risk of inducing supernumerary teeth—where extra teeth erupt in places they are not needed, potentially crowding the jaw and disrupting the alignment of existing healthy teeth—remains a primary safety concern that must be rigorously evaluated before the drug can be approved for widespread adult application.[1]

To mitigate these risks, the monoclonal antibody has been meticulously engineered for highly specific molecular interactions. TRG035 is designed to selectively interfere with USAG-1's binding to the BMP pathway, while intentionally leaving its interaction with Wnt co-receptors intact. This selective targeting is a crucial safety feature; by isolating the BMP pathway, researchers hope to maximize the regenerative potential precisely at the site of the missing tooth while minimizing off-target developmental side effects or aberrant bone growth elsewhere in the patient's body.[7]

If the Phase II trials prove successful, the economic and medical implications for the global dental market will be profound. Industry analysts project that a viable biological alternative to implants could fundamentally disrupt the multi-billion-dollar restorative dentistry sector, which has relied on the same basic mechanical principles for decades. Patients increasingly prefer preventive and regenerative care over invasive surgical procedures, and a drug that regrows natural, living tissue aligns perfectly with a broader cultural shift toward biomimetic medicine that works in harmony with the body's own systems.[3][8]

For now, the global dental community watches closely as the first human patients prepare to test the absolute limits of regenerative science. Whether TRG035 becomes a routine, over-the-counter-style treatment by the end of the decade or remains a highly specialized therapy reserved for rare genetic disorders, it has already proven that the human body retains remarkable, untapped regenerative potential. The long-held dream of coaxing the adult jaw into doing something it hasn't done since childhood—growing a brand new, living tooth—is finally stepping out of the realm of science fiction and into the reality of the clinical setting.[8]